Compugen Ltd.

339 articles with Compugen Ltd.

• Compugen Announces Addition of Immuno-oncology Pioneer Dr. Nils Lonberg to its Scientific Advisory Board

  9/30/2020

  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the addition of Nils Lonberg , Ph.D., to its Scientific Advisory Board (SAB). Dr. Lonberg is a pioneer in the field of immuno-oncology and has more than 30 years of experience in the biopha

• Compugen Doses First Patient in Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® and Anti-TIGIT Antibody

  9/8/2020

  Study accelerates evaluation of Compugen's DNAM axis hypothesis and biomarker strategy

• Compugen to Present at Upcoming September 2020 Investor Conferences

  9/3/2020

  Compugen Ltd., a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced that management will present at the following upcoming virtual investor conferences

• Compugen Expands Patent Portfolio for TIGIT Inhibitor COM902 with New US Composition of Matter Patent

  8/28/2020

  Compugen Ltd., a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced that the United States Patent and Trademark Office has granted a new patent covering the composition of matter of COM902, its immuno-oncology therapeutic antibody targeting TIGIT.

• Compugen Reports Second Quarter 2020 Results

  7/30/2020

  Initiation of triple combination study accelerating the evaluation of the DNAM axis hypothesis on-track for 2H 2020

• Compugen to Release Second Quarter 2020 Results on Thursday, July 30, 2020

  7/16/2020

  Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that the Company will release its second quarter 2020 financial results on Thursday, July 30, 2020 before the U.S. financial markets open.

• Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor

  6/1/2020

  Study to evaluate simultaneous blockade of PVRIG, TIGIT and PD-1 immune checkpoints Study to accelerate clinical evaluation of Compugen's DNAM axis hypothesis and biomarker-driven approach in advanced solid tumors to broaden patient population responsive to cancer immunotherapy On-track to begin triple combination study during second half of 2020

• Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort

  5/27/2020

  Compugen Ltd. announced that the first patient has been dosed in the monotherapy expansion cohort of its ongoing Phase 1 clinical trial of COM701, a first-in-class anti-PVRIG antibody.

• Compugen Reports First Quarter 2020 Results

  5/6/2020

  Encouraging signals of durable disease control, including confirmed partial responses in ongoing COM701 Phase 1 dose escalation study

• Compugen Presents Data Update From Ongoing Phase 1 Trial of COM701 at the 2020 AACR Virtual Annual Meeting

  4/27/2020

  COM701 was well-tolerated with no dose-limiting toxicities observed as a monotherapy and in combination with Opdivo® (nivolumab)

• Compugen to Release First Quarter 2020 Results on Wednesday, May 6, 2020

  4/23/2020

  Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that the Company will release its first quarter 2020 financial results on Wednesday, May 6, 2020 before the U.S. financial markets open.

• Compugen Expands Intellectual Property Portfolio for COM701 With New European Composition of Matter Patent

  4/22/2020

  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that The European Patent Office (EPO) has granted the Company a new patent for the composition of COM701 or backup antibodies for the treatment of cancer. EPO Patent No. 3295951 , titled "Anti-P

• Compugen Announces Publication of BAY 1905254 Preclinical Data in Cancer Immunology Research

  4/20/2020

  BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting ILDR2 immune checkpoint discovered by Compugen, is currently being evaluated by Bayer in a Phase 1 study in advanced solid tumors

• Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting

  4/14/2020

  Compugen Ltd. announced that it will present updates on its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, for the treatment of advanced solid tumors in an oral presentation at the 2020 American Association for Cancer Research Virtual Annual Meeting I on April 27, 2020 at 11:45 AM EST.

• Compugen Announces Closing of $75 Million Public Offering of Ordinary Shares

  3/17/2020

  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the closing of its previously announced underwritten public offering of 8,333,334 ordinary shares at a price to the public of $9.00 per share. The gross proceeds to Compugen from the offering we

• Compugen Announces Pricing of $75 Million Public Offering of Ordinary Shares

  3/12/2020

  Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced the pricing of an underwritten public offering of 8,333,334 ordinary shares at a price to the public of $9.00 per share.

• Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study

  3/9/2020

  COM701 demonstrates preliminary antitumor activity with confirmed partial responses as monotherapy in a patient with primary peritoneal cancer and in combination with Opdivo® (Nivolumab) in a patient with MSS-CRC

• Compugen Reports Fourth Quarter and Full Year 2019 Results

  2/20/2020

  Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the fourth quarter and full year ended December 31, 2019.

• Compugen Highlights Recent Accomplishments and Previews Upcoming Milestones

  1/9/2020

  Encouraging preliminary COM701 Phase 1 clinical data presented at SITC 2019 demonstrated initial signs of anti-tumor activity in highly refractory patient population

• Compugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development

  1/8/2020

  Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced the appointment of Oliver Froescheis, Ph.D., as Senior Vice President, Corporate and Business Development.